Recent Finacing
Recent Raise
Themis develops vaccines and immunomodulatory therapies using a proprietary measles-vaccine vector (Themaxyn), advancing a Phase-3-ready chikungunya vaccine, multiple infectious-disease and immuno-oncology programs, and manufacturing.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
